Table 4.
Number (%; 95% CI) of Toxicities and Hospitalization after Melphalan, analyzed on a per-patient basis
| Melphalan 280 | Melphalan 200 | p-value* | |||||
|---|---|---|---|---|---|---|---|
| (n=66) | (n=65) | ||||||
| Grades | Gr1 | Gr2 | Gr3 | Gr1 | Gr2 | Gr3 | |
| Mucositis | 5 | 21 | 1 | 11 | 8 | 0 | |
| Grades 2–3 Mucositis | 22 (33%;22–45%) | 8 (12%;4–20%) | 0.004 | ||||
| GI | 10 | 11 | 3 | 13 | 6 | 2 | |
| Grades 2–3 GI | 14 (21%;11–31%) | 8 (12%;4–20%) | 0.17 | ||||
| Hepatic | 0 | 0 | 0 | 1 | 0 | 0 | |
| Renal | 1 | 0 | 0 | 1 | 0 | 0 | |
| Skin | 3 | 0 | 0 | 2 | 0 | 0 | |
| Cardiac | 1 | 1 | 0 | 2 | 2 | 0 | |
| Pulmonary | 3 | 1 | 0 | 0 | 2 | 0 | |
| CNS | 0 | 1 | 0 | 0 | 0 | 0 | |
| Bladder | 1 | 1 | 0 | 0 | 0 | 0 | |
| Any Grade 2–3 | 24 (36%;25–48%) | 14 (22%;12–32%) | 0.06 | ||||
| # Patients Hospitalized | 39 (59%) | 28 (43%) | 0.08 | ||||
| Median (range) | 6 (0–33) | 0 (0–23) | 0.02 | ||||
| Hospital days | |||||||
*
compares proportion of grade 2–3 toxicity between groups for listed toxicity